DK1285080T3 - Fremgangsmåde til oprensning af alphavirusreplikonpartikler - Google Patents

Fremgangsmåde til oprensning af alphavirusreplikonpartikler

Info

Publication number
DK1285080T3
DK1285080T3 DK01941874T DK01941874T DK1285080T3 DK 1285080 T3 DK1285080 T3 DK 1285080T3 DK 01941874 T DK01941874 T DK 01941874T DK 01941874 T DK01941874 T DK 01941874T DK 1285080 T3 DK1285080 T3 DK 1285080T3
Authority
DK
Denmark
Prior art keywords
purification
alphavirus replicon
methods
replicon particles
disclosed
Prior art date
Application number
DK01941874T
Other languages
Danish (da)
English (en)
Inventor
John M Polo
Catherine Greer
Maria Calderon-Cacia
La Vega Daniel Del Jr
Thomas W Dubensky Jr
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1285080T3 publication Critical patent/DK1285080T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Powder Metallurgy (AREA)
  • Disintegrating Or Milling (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
DK01941874T 2000-05-31 2001-05-31 Fremgangsmåde til oprensning af alphavirusreplikonpartikler DK1285080T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20837600P 2000-05-31 2000-05-31
PCT/US2001/018021 WO2001092552A2 (en) 2000-05-31 2001-05-31 Method for the purification of alphavirus replicon particles

Publications (1)

Publication Number Publication Date
DK1285080T3 true DK1285080T3 (da) 2008-12-01

Family

ID=22774372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01941874T DK1285080T3 (da) 2000-05-31 2001-05-31 Fremgangsmåde til oprensning af alphavirusreplikonpartikler

Country Status (9)

Country Link
US (4) US6767699B2 (de)
EP (1) EP1285080B1 (de)
AT (1) ATE409749T1 (de)
AU (1) AU2001275191A1 (de)
CA (1) CA2410948C (de)
DE (1) DE60135983D1 (de)
DK (1) DK1285080T3 (de)
ES (1) ES2312447T3 (de)
WO (1) WO2001092552A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
CA2448066A1 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
WO2003023026A1 (en) * 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
DE60327069D1 (de) 2002-04-30 2009-05-20 Oncolytics Biotech Inc Verbesserte reinigungsmethode für viren
CA2500661A1 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
AU2003297041B2 (en) * 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
AU2003297039B2 (en) * 2002-12-13 2009-03-05 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
EP1608762B1 (de) * 2003-03-20 2014-01-08 Alphavax, Inc. Verbesserte alphavirus replikons und helferkonstrukt
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
EP1736538A1 (de) 2005-06-21 2006-12-27 Cytos Biotechnology AG Prozess für die preparative Reinigung von Virus-ähnlichen Partikeln (VLPs)
KR100760525B1 (ko) * 2006-04-13 2007-10-04 김재만 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
US20090022760A1 (en) * 2006-09-12 2009-01-22 Alphavax Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
US20090047255A1 (en) * 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
DK2947149T3 (en) 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
US8680258B2 (en) 2008-12-01 2014-03-25 Alphavax, Inc. Use of microRNAs to control virus helper nucleic acids
CA2748788C (en) 2009-01-05 2021-02-09 Epitogenesis Inc. The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
US10072307B1 (en) 2009-01-23 2018-09-11 Colorado State University Research Foundation Isolation of viruses using anionic resin beads
AU2010234362B2 (en) 2009-04-08 2015-11-26 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
WO2012015908A2 (en) 2010-07-30 2012-02-02 Millipore Corporation Chromatography media and method
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
EP2723378A4 (de) 2011-06-24 2015-01-28 Epitogenesis Inc Pharmazeutische zusammensetzungen mit einer kombination aus ausgewählten trägern, vitaminen, tanninen und flavonoiden als antigenspezifischen immunmodulatoren
EP3068867B1 (de) 2013-11-16 2018-04-18 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
EP3188816B1 (de) 2014-09-02 2021-06-09 EMD Millipore Corporation Chromatographie-medum, bestehend aus diskreten porösen bündeln von nanofibrillen
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
ES2950887T3 (es) 2015-12-23 2023-10-16 Valneva Austria Gmbh Purificación del Virus Zika
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN118662621A (zh) 2017-09-21 2024-09-20 瓦尔尼瓦公司 包含免疫原性屈公病毒chikv-delta5nsp3的医药组成物的制备方法
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
AU2024208643A1 (en) 2023-01-12 2025-06-26 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
US20260218164A1 (en) * 2023-01-30 2026-07-30 Thermo Finnigan Llc Separation of long oligonucleotides

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466788A (en) * 1985-03-07 1995-11-14 Mycogen Plant Science, Inc. Subgenomic promoter
ES8800988A1 (es) 1985-04-05 1987-12-16 Meloy Lab Procedimiento de producir interferona humana.
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
AU7780687A (en) 1986-07-23 1988-02-10 Aphton Corp. Immunogens and improved methods of making immunogens
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5093239A (en) 1988-05-02 1992-03-03 Eastman Kodak Company Reagents for detecting oxidase positive microorganisms
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5026686A (en) 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
EP1001032A3 (de) 1989-08-18 2005-02-23 Chiron Corporation Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
DE4315109A1 (de) 1993-05-06 1994-11-10 Inst Pflanzengenetik & Kultur Verfahren und Vektorkonstrukt zur Expressionssteigerung von Transgenen
ATE250670T1 (de) 1993-07-06 2003-10-15 Univ Nice Sophia Antipolis Vektor, enthält ein bei arn-polymerase-iii transcriptes virus-gen
US5837503A (en) 1993-07-07 1998-11-17 Universite De Nice-Sophia-Antipolis Vector containing viral gene transcribed by RNA polymerase III and methods for use
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
IL112371A0 (en) 1994-01-25 1995-03-30 Res Dev Foundation A novel protein from aedes albopictus cells and methods for its use
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
US5532154A (en) 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
JPH11511326A (ja) * 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびaavの精製
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
EP0871747A1 (de) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunstimulierung vermittelt durch genmodifizierte dendritische zellen
EP0880587A1 (de) 1996-02-15 1998-12-02 Chiron Corporation Methode zur gentherapie mittels fgf-s
ES2301178T3 (es) 1996-04-05 2008-06-16 Novartis Vaccines & Diagnostic Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AU3210997A (en) 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US5843712A (en) 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
WO1998013511A1 (en) 1996-09-25 1998-04-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
AU729690B2 (en) 1996-10-10 2001-02-08 Henrik Garoff Alphavirus-retrovirus vectors
WO1998026084A1 (en) 1996-12-09 1998-06-18 Wolfgang Andreas Renner Expression of active interferon beta 1 using recombinant rna replicons
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6261570B1 (en) 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
EP0996737A1 (de) 1997-08-15 2000-05-03 Inex Pharmaceuticals Corp. Vom semliki-forest-virus abgeleitete vektoren für den gentransfer in nicht-endotheliale, kardiovaskuläre zellen
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
ATE298371T1 (de) 1997-09-24 2005-07-15 Univ California Nicht-primaten lentivirale vektoren und verpackungssysteme
CA2309835A1 (en) 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors
AU749345B2 (en) 1997-11-14 2002-06-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
CA2309765A1 (en) 1997-12-18 1999-06-24 G.D. Searle & Co. Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity

Also Published As

Publication number Publication date
ES2312447T3 (es) 2009-03-01
WO2001092552A2 (en) 2001-12-06
AU2001275191A1 (en) 2001-12-11
ATE409749T1 (de) 2008-10-15
EP1285080B1 (de) 2008-10-01
US20020015945A1 (en) 2002-02-07
US20120231526A1 (en) 2012-09-13
US6767699B2 (en) 2004-07-27
US20050112752A1 (en) 2005-05-26
US20100055128A1 (en) 2010-03-04
DE60135983D1 (de) 2008-11-13
CA2410948A1 (en) 2001-12-06
WO2001092552A3 (en) 2002-05-23
CA2410948C (en) 2012-07-17
EP1285080A2 (de) 2003-02-26

Similar Documents

Publication Publication Date Title
DE60135983D1 (de) Verfahren zur reinigung von alphaviralen replikon partikeln
ATE472335T1 (de) Chimere alphavirus-replikon-partikel
ATE420965T1 (de) Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
SG10201909381WA (en) Production of oversized adeno-associated vectors
EP0757717A4 (de) Papillomavirus vakzine
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
PH12021551633A1 (en) Prostate neoantigens and their uses
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
TW200635596A (en) Pyridazinone compounds
WO2005035556A3 (en) Sars-coronavirus virus-like particles and methods of use
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
MX2022014161A (es) Vacunas contra sars-cov-2.
MX2015003717A (es) Polipeptidos del virus de chikungunya que expresan el virus de sarampion recombinante y sus aplicaciones.
EP1474121A4 (de) Kleine moleküle als antagonisten von proteinen der bcl2-familie
ATE321853T1 (de) Humanische pellino-polypeptide
WO2008027560A3 (en) Holin-enhanced vaccines and reagents, and methods of use thereof
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
ATE408013T1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
DK1423525T3 (da) Rekombinant MVA, der kan eksprimere HCV-strukturantigener
WO2007046839A3 (en) New live virus vaccines
EP4410970A3 (de) Effizientes zellkultursystem für hepatitis-c-virus-genotyp 6a
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
WO2001090302A3 (en) Compositions and methods for production of rna viruses and rna virus-based vector particles
ATE263234T1 (de) Veränderte, kleine rna-viren
YU16292A (sh) Novi etnomopoksvirusni ekspresioni sistem